Milrinone During Living Donor Hepatectomy

Hepatectomy Clinical Trial

Official title:

Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00966745
• Other study ID #: mil_living_liver_donor
• Status: Completed
• Phase: N/A
• First received: August 13, 2009
• Last updated: August 26, 2009
• Start date: January 2008
• Est. completion date: December 2008

Study information

• Verified date: August 2009
• Source: Seoul National University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug AdministrationKorea: Ministry for Health and Welfare
• Study type: Interventional

Clinical Trial Summary

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

• Living liver donors

Exclusion Criteria:

• Donors with concurrent cardiac, pulmonary, and urologic disease

• Hepatectomy performed laparoscopically

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatectomy

Intervention

Drug:
• milrinone

• placebo

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	condition of surgical field		intraoperative period (from the start of surgery to end of living donor hepatectomy)	No
Secondary	the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively		intraoperative period (from the start of surgery to end of living donor hepatectomy)	No